Nurix Therapeutics and Roche forge $2.3B global collaboration
Nurix Therapeutics (NASDAQ:NRIX) announced on June 8, 2026, that it has entered into a global licensing and collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg (NX-5948).










